Benitec Biopharma (ASX:BLT) Current Accrued Expense : A$2.65 Mil (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Benitec Biopharma Current Accrued Expense?

Benitec Biopharma's Current Accrued Expense for the quarter that ended in Mar. 2024 was A$2.65 Mil.

Benitec Biopharma's quarterly Current Accrued Expense declined from Sep. 2023 (A$3.46 Mil) to Dec. 2023 (A$3.35 Mil) and declined from Dec. 2023 (A$3.35 Mil) to Mar. 2024 (A$2.65 Mil).

Benitec Biopharma's annual Current Accrued Expense increased from Jun. 2021 (A$0.64 Mil) to Jun. 2022 (A$1.97 Mil) and increased from Jun. 2022 (A$1.97 Mil) to Jun. 2023 (A$3.01 Mil).

Benitec Biopharma Current Accrued Expense Historical Data

The historical data trend for Benitec Biopharma's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Current Accrued Expense Chart

Benitec Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Current Accrued Expense

Get a 7-Day Free Trial

1.36

0.37

0.64

1.97

3.01

Benitec Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Current Accrued Expense	Get a 7-Day Free Trial															2.67	3.01	3.46	3.35	2.65

Benitec Biopharma Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Benitec Biopharma Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Benitec Biopharma (ASX:BLT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (ASX:BLT) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

BNTC:USA

Address

3940 Trust Way, Hayward, CA, USA, 94545

Website

https://www.benitec.com

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.